Showing results (291-300 of 318) with videos related to
Sort By:
Pageof 32
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.Oncotarget|October 24, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.Breast (Edinburgh, Scotland)|April 28, 2026
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 studyFrancesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, et al.Journal of the National Cancer Institute. Monographs|November 2, 2011
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)Alfredo Berruti, Daniele Generali, Manfred Kaufmann, et al.The Oncologist|March 12, 2022
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Jean-Yves Pierga, James M Reuben, et al.Oncotarget|August 31, 2018
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.Therapeutic Advances in Medical Oncology|January 22, 2024
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registryBruno Vincenzi, Alessio Cortellini, Alessandro Mazzocca, et al.Breast (Edinburgh, Scotland)|January 31, 2026
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled AnalysisWolfgang Janni, Thomas W P Friedl, Tracy C Yab, et al.Pageof 32